374 related articles for article (PubMed ID: 27538576)
1. Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups.
de Velasco G; Miao D; Voss MH; Hakimi AA; Hsieh JJ; Tannir NM; Tamboli P; Appleman LJ; Rathmell WK; Van Allen EM; Choueiri TK
Cancer Immunol Res; 2016 Oct; 4(10):820-822. PubMed ID: 27538576
[TBL] [Abstract][Full Text] [Related]
2. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
3. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.
Escudier B; Sharma P; McDermott DF; George S; Hammers HJ; Srinivas S; Tykodi SS; Sosman JA; Procopio G; Plimack ER; Castellano D; Gurney H; Donskov F; Peltola K; Wagstaff J; Gauler TC; Ueda T; Zhao H; Waxman IM; Motzer RJ;
Eur Urol; 2017 Dec; 72(6):962-971. PubMed ID: 28262413
[TBL] [Abstract][Full Text] [Related]
4. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
[TBL] [Abstract][Full Text] [Related]
6. Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy.
Venur VA; Joshi M; Nepple KG; Zakharia Y
Drug Des Devel Ther; 2017; 11():1175-1182. PubMed ID: 28442891
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.
George S; Motzer RJ; Hammers HJ; Redman BG; Kuzel TM; Tykodi SS; Plimack ER; Jiang J; Waxman IM; Rini BI
JAMA Oncol; 2016 Sep; 2(9):1179-86. PubMed ID: 27243803
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.
Choueiri TK; Fishman MN; Escudier B; McDermott DF; Drake CG; Kluger H; Stadler WM; Perez-Gracia JL; McNeel DG; Curti B; Harrison MR; Plimack ER; Appleman L; Fong L; Albiges L; Cohen L; Young TC; Chasalow SD; Ross-Macdonald P; Srivastava S; Jure-Kunkel M; Kurland JF; Simon JS; Sznol M
Clin Cancer Res; 2016 Nov; 22(22):5461-5471. PubMed ID: 27169994
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.
Flippot R; Escudier B; Albiges L
Drugs; 2018 Sep; 78(14):1443-1457. PubMed ID: 30187355
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
Motzer RJ; Rini BI; McDermott DF; Redman BG; Kuzel TM; Harrison MR; Vaishampayan UN; Drabkin HA; George S; Logan TF; Margolin KA; Plimack ER; Lambert AM; Waxman IM; Hammers HJ
J Clin Oncol; 2015 May; 33(13):1430-7. PubMed ID: 25452452
[TBL] [Abstract][Full Text] [Related]
12. [Immunotherapy for renal cell carcinoma - current status].
Grimm MO; Foller S
Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324
[TBL] [Abstract][Full Text] [Related]
13. Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma.
Matsushita H; Sato Y; Karasaki T; Nakagawa T; Kume H; Ogawa S; Homma Y; Kakimi K
Cancer Immunol Res; 2016 May; 4(5):463-71. PubMed ID: 26980598
[TBL] [Abstract][Full Text] [Related]
14. Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era.
Naito S; Kato T; Numakura K; Hatakeyama S; Koguchi T; Kandori S; Kawasaki Y; Adachi H; Kato R; Narita S; Yamamoto H; Ogawa S; Kawamura S; Obara W; Ito A; Nishiyama H; Kojima Y; Ohyama C; Habuchi T; Tsuchiya N
Int J Clin Oncol; 2021 Oct; 26(10):1947-1954. PubMed ID: 34191191
[TBL] [Abstract][Full Text] [Related]
15. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
[TBL] [Abstract][Full Text] [Related]
16. Is Memorial Sloan-Kettering Cancer Center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era?
Shinohara N; Abe T; Mochizuki T; Kashiwagi A; Kanagawa K; Maruyama S; Sazawa A; Oba K; Nonomura K
Urol Oncol; 2013 Oct; 31(7):1276-82. PubMed ID: 21956045
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers to predict prognosis and response to checkpoint inhibitors.
Yuasa T; Masuda H; Yamamoto S; Numao N; Yonese J
Int J Clin Oncol; 2017 Aug; 22(4):629-634. PubMed ID: 28382562
[TBL] [Abstract][Full Text] [Related]
18. A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma.
Betancor YZ; Ferreiro-Pantín M; Anido-Herranz U; Fuentes-Losada M; León-Mateos L; García-Acuña SM; Vaamonde-Rodríguez V; García-Pinel B; Cebey-López V; Villaverde-Viaño R; Lombardía-Rodríguez H; Kotrulev M; Fernández-Díaz N; Gomez-Tourino I; Fernández-Baltar C; García-González J; Tubio JMC; López-López R; Ruiz-Bañobre J
Front Immunol; 2024; 15():1374728. PubMed ID: 38660294
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification and bone metastasis in Chinese patients with metastatic renal cell carcinoma.
Zhang Y; Li Y; Cai Y; Wang K; Li H
Cell Oncol (Dordr); 2016 Feb; 39(1):15-21. PubMed ID: 26597814
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database.
Yekedüz E; Ertürk İ; Tural D; Karadurmuş N; Karakaya S; Hızal M; Arıkan R; Arslan Ç; Taban H; Küçükarda A; Öztaş NŞ; Sever ÖN; Uçar G; Can O; Şendur MA; Demirci U; Kılıçkap S; Çiçin İ; Öksüzoğlu B; Özgüroğlu M; Ürün Y
Future Oncol; 2021 Dec; 17(35):4861-4869. PubMed ID: 34726480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
